Benzinga's Top #PreMarket Losers - Esperion Therapeutics (NASDAQ:ESPR), bluebird bio (NASDAQ:BLUE)

Crypto Whales Are Loading Up — Are You?

New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.

Esperion Therapeutics Inc (NASDAQ: ESPR) shares dropped 11.32 percent to $89.15 in pre-market after falling 0.24 percent on Tuesday.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Francesca's Holdings Corp (NASDAQ: FRAN) shares fell 5.16 percent to $15.25 in pre-market trading. Francesca's reported Q4 earnings of $0.17 per share on revenue of $95 million. The company expected Q2 earnings of $0.81 to $0.90 per share, on revenue of $104 million to $107 million. Regeneron Pharmaceuticals Inc (NASDAQ: REGN) shares declined 3.34 percent to $508.50 in pre-market trading. The FDA Panel has recommended the approval of Sanofi and Regeneron's Praluent.

Gulfport Energy Corporation (NASDAQ: GPOR) shares tumbled 2.82 percent to $44.09 in pre-market trading. Gulfport Energy announced an offering of 10 million common shares. bluebird bio Inc (NASDAQ: BLUE) fell 2.63 percent to $181.73 in pre-market trading after dropping 1.05 percent on Tuesday.